Osteopontin: an emerging therapeutic target for anticancer therapy

被引：81

作者：

Jain, Shalini ^{[1
]}

Chakraborty, Goutam ^{[1
]}

Bulbule, Anuradha ^{[1
]}

Kaur, Rajinder ^{[1
]}

Kundu, Gopal C. ^{[1
]}

机构：

[1] Natl Ctr Cell Sci, Pune 411007, Maharashtra, India

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2007年 / 11卷 / 01期

关键词：

metastasis; osteopontin; prognostic marker; tumour progression;

D O I：

10.1517/14728222.11.1.81

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

Distant migration of malignant cells or metastasis is considered one of the hallmarks of tumour progression and makes cancer a most deadly disease. The elevated expression of osteopontin (OPN), a metastasis-associated small integrin-binding ligand Winked glycoprotein family member has been observed in several cancers and, thus, this protein is considered as a potent prognostic marker during tumour progression. OPN regulates a series of signalling cascades and augments the expression of several oncogenic molecules. Therefore, understanding the molecular mechanism and the signalling pathways by which OPN promotes tumorigenesis may be helpful in designing a novel anticancer therapy. At present, the role of OPN in regulating cancer progression is the subject of intense investigation and targeting OPN might be an appropriate therapeutic strategy for the treatment of cancer. This review is focused on OPN-based anticancer therapy, which may provide a new dimension for the successful treatment of cancer.

引用

页码：81 / 90

页数：10

共 93 条

[1]

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion [J].